In cooperation with Enthera, YUMAB generated Ent001, a stabilized IgG4, without the need for bioinformatic engineering to reach an affinity to TMEM in the lower pM range. Ent001 specifically binds to TMEM219 inhibiting its interaction with IGFBP3. With the lead antibody Ent001 YUMAB enabled Enthera to conduct successful preclinical development studies and to proceed with clinical trials in human to treat moderate to severe acute ulcerative colitis.
